[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.16\u2033 kilitli=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_row _builder_version=\u201d4.16\u2033 arka plan_size=\u201dinitial\u201d arka plan_position=\u201dtop_left\u201d arka plan_repeat=\u201dtekrar\u201d global_colors_info=\u201d{ }\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d g\u00f6renek_padding__hover=\u201d|||\u201d][et_pb_text _builder_version=\u201d4.21.0\u2033 ba\u015fl\u0131k_2_font_size=\u201d24px\u201d ba\u015fl\u0131k_2_line_height=\u201d1.4em\u201d arka plan_size=\u201dinitial\u201d arka plan_pozisyon=\u201dtop_left\u201d arka plan_repeat=\u201dtekrar\u201d \u00f6zel_padding =\u201d25px||||false|false\u201d global_colors_info=\u201d{}\u201d]<\/p>\n
Ka\u00e7\u0131r\u0131lm\u0131\u015f bir kanser te\u015fhisi y\u0131k\u0131c\u0131 olabilir. Ancak di\u011fer malignitelerden farkl\u0131 olarak a\u011f\u0131z kanserinin ya\u015fam\u0131 tehdit eden a\u015famalara kadar fark edilmeden ilerlemesi daha olas\u0131d\u0131r. Bunun temel nedeni erken evre belirti ve semptomlar\u0131n yanl\u0131\u015f te\u015fhis edilmesidir. Bir vaka incelemesi, a\u011f\u0131z kanseri atlanan 35 hasta aras\u0131nda en yayg\u0131n yanl\u0131\u015f te\u015fhislerin \u015funlar oldu\u011funu buldu:1<\/sup><\/p>\n Ne yaz\u0131k ki, bu model genellikle a\u011f\u0131z kanseri olan hastalar i\u00e7in bir normdur. Asl\u0131nda vakalar\u0131n \u00fc\u00e7te ikisinden fazlas\u0131na daha sonraki a\u015famalarda te\u015fhis konuluyor.2<\/sup> Bu endi\u015fe verici istatistik, 'lik hayatta kalma oran\u0131n\u0131n temel nedenidir.3<\/sup> Ancak geri kalan i\u00e7in hayatta kalma, zay\u0131flat\u0131c\u0131 tedavi ve ya\u015fam kalitesinin d\u00fc\u015fmesi anlam\u0131na gelebilir.<\/p>\n A\u015fama III ve IV'teki a\u011f\u0131z kanserini tedavi etmek hem hastalar hem de sa\u011flay\u0131c\u0131lar i\u00e7in zorludur. En iyi sonu\u00e7lar\u0131 elde etmek i\u00e7in sa\u011flay\u0131c\u0131lar kemoterapi, radyasyon ve cerrahi tedavinin bir kombinasyonunu kullanmay\u0131 se\u00e7ebilirler. Bu prosed\u00fcrler son derece invazivdir ve sa\u011fl\u0131kl\u0131 dokular\u0131n \u00e7\u0131kar\u0131lmas\u0131n\u0131 i\u00e7erebilir, bu da kal\u0131c\u0131 \u015fekil bozuklu\u011funa, uzun s\u00fcreli a\u011fr\u0131ya ve normal i\u015flevlerin yerine getirilmesinde sorunlara yol a\u00e7abilir. Kapsaml\u0131 eksizyon ve\/veya diseksiyon yap\u0131lacak hastalar\u0131n dudak, dil, \u00e7ene kemi\u011fi, sert damak ve ses kutusu gibi temel yap\u0131lar olmadan ya\u015famaya haz\u0131rlanmalar\u0131 gerekir.4<\/sup><\/p>\n Bu tedavi protokol\u00fc i\u015fe yarasa bile, hastalar\u0131n g\u00fcnl\u00fck aktiviteleri nas\u0131l ger\u00e7ekle\u015ftireceklerini yeniden \u00f6\u011frenmek i\u00e7in y\u0131llarca s\u00fcren kapsaml\u0131 fiziksel, mesleki ve konu\u015fma terapisine tabi tutulmas\u0131 gerekir. Ayr\u0131ca kemoterapi ve radyasyon tedavisinin uzun vadeli yan etkilerinden de muzdariptirler.<\/p>\n Hastalar fiziksel y\u00fck\u00fcn yan\u0131 s\u0131ra y\u00fcksek tedavi maliyetleriyle de kar\u015f\u0131 kar\u015f\u0131ya kal\u0131yor. Kanser tedavisi do\u011fas\u0131 gere\u011fi pahal\u0131d\u0131r ve denkleme rekonstr\u00fcktif cerrahi ile di\u015f veya y\u00fcz protezlerinin eklenmesi yaln\u0131zca mali y\u00fck\u00fcn artmas\u0131na hizmet eder. Geriye d\u00f6n\u00fck bir talep analizi, birden fazla tedavi bi\u00e7iminin kullan\u0131lmas\u0131n\u0131n, tek y\u00f6ntemli tedaviden iki kat daha pahal\u0131 oldu\u011funu ortaya \u00e7\u0131kard\u0131.5<\/sup> Ortalama olarak, kemoterapiye, radyasyona ve ameliyata ihtiya\u00e7 duyan ilerlemi\u015f a\u011f\u0131z kanseri hastalar\u0131n\u0131n ticari sa\u011fl\u0131k sigortas\u0131ndan sonra 153.000 dolar\u0131n \u00fczerinde sa\u011fl\u0131k faturas\u0131 vard\u0131.5<\/sup><\/p>\n \u015eekil bozucu ve ya\u015fam\u0131 de\u011fi\u015ftiren tedavilerden muazzam bak\u0131m maliyetlerine kadar, ileri evre a\u011f\u0131z kanseri te\u015fhisinden sa\u011f \u00e7\u0131kmak, hastan\u0131n ya\u015fam kalitesini h\u00e2l\u00e2 bozabilir. Tedavinin nihai amac\u0131 hayatta kalmak olsa da, sa\u011flay\u0131c\u0131lar odaklar\u0131n\u0131 \"iyi\" bir sonucun nas\u0131l g\u00f6r\u00fcnece\u011fini, yani daha az invazif tedavi ve daha d\u00fc\u015f\u00fck mali y\u00fck\u00fc yeniden tan\u0131mlamaya kayd\u0131rmal\u0131d\u0131r.<\/p>\n Bu, erken tespit i\u00e7in sekt\u00f6r \u00e7ap\u0131nda bir \u00e7aba gerektirir. Uygun tarama teknikleri ve proaktif m\u00fcdahale ile hastalar sadece hayatta kalma \u015fanslar\u0131n\u0131 artt\u0131rmakla kalmaz, ayn\u0131 zamanda tedavi sonras\u0131nda da y\u00fcksek ya\u015fam kalitesini koruyabilirler. Vigilant Biosciences\u00ae\u00ae olarak, d\u00fcnya \u00e7ap\u0131ndaki sa\u011flay\u0131c\u0131lar\u0131n a\u011f\u0131z kanserini daha erken te\u015fhis etmek ve hasta sonu\u00e7lar\u0131n\u0131 iyile\u015ftirmek i\u00e7in tespit \u00e7abalar\u0131n\u0131 desteklemelerine yard\u0131mc\u0131 oluyoruz.<\/p>\n Vigilant Biosciences\u00ae\u00ae'\u0131n a\u011f\u0131z kanseri tespitini nas\u0131l h\u0131zland\u0131rd\u0131\u011f\u0131 hakk\u0131nda daha fazla bilgi edinin.<\/a><\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u201d4.21.0\u2033 text_font_size=\u201d14px\u201dheader_2_font_size=\u201d24px\u201dheader_2_line_height=\u201d1.4em\u201dbackground_size=\u201dinitial\u201dbackground_position=\u201dtop_left\u201dbackground_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d ]<\/p>\n Kaynaklar<\/strong><\/p>\n 1. Daniel, M. ve Rogers, S.N. (2022). A\u011f\u0131z kanseri olan hastalar\u0131n sevkinde mesleki gecikmeler: alt\u0131 vaka \u00f6yk\u00fcs\u00fc. \u0130ngiliz Di\u015f Dergisi 233(12), 1003-1008. [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":" Ka\u00e7\u0131r\u0131lm\u0131\u015f bir kanser te\u015fhisi y\u0131k\u0131c\u0131 olabilir. Ancak di\u011fer malignitelerden farkl\u0131 olarak a\u011f\u0131z kanserinin ya\u015fam\u0131 tehdit eden a\u015famalara kadar fark edilmeden ilerlemesi daha olas\u0131d\u0131r. Bunun temel nedeni erken evre belirti ve semptomlar\u0131n yanl\u0131\u015f te\u015fhis edilmesidir. Bir vaka incelemesinde, a\u011f\u0131z kanseri atlanan 35 hasta aras\u0131nda en yayg\u0131n yanl\u0131\u015f te\u015fhislerin \u015funlar oldu\u011fu ortaya \u00e7\u0131kt\u0131:1 Parestezi Di\u015f apsesi Temporomandibular [\u2026]<\/p>","protected":false},"author":3,"featured_media":469,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-454","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"\n\n
Ge\u00e7 A\u015fama Tan\u0131n\u0131n Sonu\u00e7lar\u0131<\/h2>\n
Erken Tespit Giri\u015fimlerinin G\u00fc\u00e7lendirilmesi<\/h2>\n
2. A\u011f\u0131z ve Orofaringeal Kanser: \u0130statistikler. (Ekim 2022). Kanser.Net. https:\/\/www.cancer.net\/cancer-types\/oral-and-oropharyngeal-cancer\/statistics<\/a>
3. Gonz\u00e1lez-Moles, M.\u00c1., Aguilar-Ruiz, M. ve Ramos-Garc\u00eda, P. (2022). A\u011f\u0131z Kanserinin Erken Tan\u0131s\u0131ndaki Zorluklar, Kan\u0131t Eksiklikleri ve \u0130yile\u015ftirme Stratejileri: Sistematik \u0130ncelemelerin Kapsaml\u0131 Bir \u0130ncelemesi. Kanserler 14(19), 4967.
4. A\u011f\u0131z Bo\u015flu\u011fu ve Orofaringeal Kanser Cerrahisi. (tarih yok). Amerikan Kanser Toplulu\u011fu. 18 May\u0131s 2023'te \u015fu adresten al\u0131nd\u0131: https:\/\/www.cancer.org\/cancer\/types\/oral-cavity-and-oropharyngeal-cancer\/treating\/surgery.html<\/a>
5. Jacobson, J.J., Epstein, J.B., Eichmiller, F.C., Gibson, T.B., Carls, G.S., Vogtmann, E., Wang, S., Murphy, B. (2012). Oral, oral faringeal ve t\u00fck\u00fcr\u00fck bezi kanserlerinin maliyet y\u00fck\u00fc \u00fc\u00e7 gruptad\u0131r: ticari sigorta, Medicare ve Medicaid. Ba\u015f ve Boyun Onkolojisi 4, 15.<\/p>\n